Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
University of Washington
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Celgene
Mayo Clinic
University of Chicago
Medical College of Wisconsin
CStone Pharmaceuticals
The University of Texas Health Science Center at San Antonio
National Cancer Institute (NCI)
Northwestern University
Guangzhou Lupeng Pharmaceutical Company LTD.
Stanford University
Hoffmann-La Roche
University of Pittsburgh
Dana-Farber Cancer Institute
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
Therapeutic Advances in Childhood Leukemia Consortium
Children's Oncology Group
Fred Hutchinson Cancer Center
University of Washington
Fate Therapeutics
National Institutes of Health Clinical Center (CC)
University of Miami
Weill Medical College of Cornell University
ADC Therapeutics S.A.
University of California, Davis
National Institutes of Health Clinical Center (CC)
National Institute of Allergy and Infectious Diseases (NIAID)
Children's Oncology Group
University of Washington
St. Jude Children's Research Hospital
OHSU Knight Cancer Institute
Acrotech Biopharma Inc.
University of Wisconsin, Madison
Chipscreen Biosciences, Ltd.
Therapeutic Advances in Childhood Leukemia Consortium
University of Cologne
UNC Lineberger Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
H. Lee Moffitt Cancer Center and Research Institute
Seagen Inc.
Presage Biosciences
Ohio State University Comprehensive Cancer Center